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The first dichloroplatinum(II) conjugates of dicarba analogues of 
octreotide, which is expected to act as a ‘tumor-targeting device’, 
have been efficiently synthesized following a stepwise solid-phase 
approach. These compounds emulate the mechanism of cisplatin 10 
since they form a 1,2-intrastrand cross-link with two consecutive 
guanines of an oligonucleotide. 
More than 30 years after its discovery, cis-
diamminedichloroplatinum(II), cisplatin, and its analogues are 
still among the most effective anticancer drugs in clinical 15 
use.1 However, the high toxicity and the inherent or acquired 
resistance have prompted researchers to explore new 
strategies based on trans, bifunctional and multifunctional 
platinum compounds, platinum(IV) prodrugs2 or even 
alternative metal ions such as ruthenium.3 In this context, a 20 
major challenge in therapy is to achieve the specific delivery 
of metal-based drugs to cancer cells. This would reduce drug 
toxicity because normal tissues would not be affected. With 
this idea in mind, some authors have recently reported the 
conjugation of platinum complexes to carrier molecules such 25 
as folate, peptides that target tumor vasculature or even 
carbon nanotubes.4  
 In our case we have focused on somatostatin, a potent 
endocrine hormone implicated in the regulation of many 
physiological processes, such as secretion, cell division, 30 
proliferation and apoptosis, which are modulated by five G-
protein-coupled receptors (sst1-5) located in the cell 
membrane.5 Although all receptors are expressed to some 
degree in different tumors, the overexpression of subtype sst2 
is by far the most important and this fact has been exploited to 35 
deliver radionuclides for molecular imaging or cytotoxic 
agents into tumor cells.6 In order to overcome the short half-
life of somatostatin in vivo, hundreds of peptide and non-
peptide analogues have been synthesized, including octreotide 
1, a potent metabolically-stabilized cyclooctapeptide agonist 40 
that displays high affinity and specificity to sst2 receptor 
subtype.7  
 Herein we report on the solid-phase synthesis and 
characterization of the first dichloroplatinum(II) complex 
conjugated to octreotide analogues (Scheme 1), as well as 45 
DNA interaction studies. Since in these conjugates the peptide 
moiety is expected to act as a ‘tumor-targeting device’, the 
metallic complex must not alter either the pharmacophore 
sequence, Phe7-D-Trp8-Lys9-Thr10, or the β-turn structure 
stabilized by the disulfide bond, both of which are 50 
fundamental elements for the binding to the receptor. 
 
Scheme 1 Structure of the compounds synthesized.  
 First, as a cisplatin analogue we chose cis-dichloro-(1-
(carboxylic acid)-1,2-diaminoethane)platinum(II) complex 55 
([PtCl2(dap)]), 2, since the carboxylic function allows the 
attachment to an amine group of the peptide through an amide 
bond. This complex was synthesized by reaction between (±) 
2,3-diaminopropionic acid and K2PtCl4.
8  
 Given the kinetic preference of platinum(II) compounds for 60 
sulfur-containing species, we were concerned about the 
stability of the target conjugate between octreotide and 2. 
Indeed, the reaction with intracellular thiols such as 
glutathione has been postulated as the main mechanism of 
deactivation of cisplatin and, in some cases, platinum(II) 65 
complexes can react and cleave disulfide bonds.9 Moreover, a 
recent study has revealed that octreotide forms two adducts 
upon reaction with [Pt(en)Cl2], although the disulfide bond 
does not to participate.10  
 With these precedents in mind, we carried out a preliminary 70 
assay in solution by reacting octreotide with 2 using EDC and 
N-hydroxysuccinimide as coupling reagents in DMF. After 24 
h, reversed-phase HPLC analysis showed the formation of a 
main peak (Fig. 1) which was isolated and characterized by 
ESI and MALDI-TOF mass spectrometry as the expected 75 
dichloroplatinum(II) conjugate of octreotide, 3, with a single 
platinum unit. However, its low stability in water (Fig. 1) 
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precludes any biological application as well as the 
determination of the binding site (two regioisomers might be 
produced upon the formation of the amide bond with either 
the N-terminus or the side-chain of Lys9). To our surprise, MS 
analysis revealed that in all the side-products a chloride ligand 5 
had been lost and that the disulfide bond was not cleaved, 
suggesting the formation of several adducts differing in the 
ligands in the sphere of coordination of the metal.  
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Fig. 1 Reversed HPLC traces for conjugate 3: reaction crude (a), purified 10 
(b) and after standing for 24 h in H2O (c). 
 On basis of these results, we focused our work on the 
synthesis of an octreotide analogue, replacing the disulfide 
linkage with a cystine isostere. Given the high affinity of 
platinum(II) for the thioether group, we chose CH=CH and 15 
CH2-CH2 linkages since both dicarba analogues of octreotide 
(4 and 5, respectively; Scheme 1) retain relatively high 
binding affinity toward the sst2 receptor.
11 Furthermore, on-
resin ring closing metathesis (RCM) and hydrogenation 
reactions can be used to generate such analogues.11,12 Thus, 20 
we envisaged a stepwise solid-phase strategy to 
regioselectively introduce the platinum(II) moiety at the N-
terminal end of both octreotide analogues through a spacer to 
keep it away from the pharmacophore sequence (Scheme 2).  
 The linear peptide precursor was assembled manually on a 25 
Rink amide resin using standard Fmoc/tBu methodology. 
Once the Fmoc-protected threoninol functionalized as the p-
carboxybenzaldehyde acetal13 had been incorporated, the 
subsequent Fmoc-protected amino acid derivatives, including 
allyl glycine replacing both cysteines and γ-aminoisobutyric 30 
acid, were incorporated using HATU as a coupling reagent. 
Finally, RCM was assayed with second-generation Grubbs 
catalyst (0.2 eq) at 40ºC for 18 h in the presence of LiCl to 
minimize aggregation. However, HPLC analysis of an aliquot 
of resin-cleaved, deprotected peptides (TFA/TIS/H2O 35 
95:2.5:2.5) revealed that only 56% of the linear peptide had 
been cyclised. We repeated the reaction under microwave 
irradiation14 for 1 h at 100ºC and, surprisingly, the efficiency 
of the RCM was dramatically improved (cyclic/linear peptide 
93:7, 2:1 mixture of cis and trans diastereomers, respectively) 40 
and no oligomerization products were detected, even using a 
relatively high resin loading (0.34 mmol/g). The configuration 
of the double bond was unambiguously established by NMR 
spectroscopy since a relatively strong NOE between both 
olefinic protons was only found in the major isomer.  45 
 Hydrogenation of unsaturated peptide-resin was 
accomplished using Wilkinson’s catalyst (0.3 eq) for 24 h at 
50ºC under hydrogen pressure (50 Bar). Again, HPLC and 
high- resolution MS analysis revealed a quantitative reduction 
of the double bond under the optimized conditions.  50 
 The final step was the linking of the metallic complex onto 
both cyclic peptide-resins. Once Fmoc group of the spacer had 
been removed, 2 was coupled using DIPC and HOSu (15 h at 
rt protected from light). Since TIS scavenger has been 
described to reduce PtCl2 moiety to metallic platinum,
15 we 55 
carried out cleavage from the resin and removal of protecting 
groups with a TFA/phenol/H2O cocktail (95:2.5:2.5). As 
shown in Fig. 2, two sets of double peaks (73%, 1:2 relative 
ratio) were obtained for the unsaturated conjugate 6 which 
accounts from the presence of cis and trans isomers as well as 60 
from the use of a racemic platinum(II) complex. All four 
diastereomers were isolated by preparative HPLC and 
characterized by MS as the expected dichloroplatinum(II)-
octreotide conjugates. Similar results were obtained for the 
saturated conjugate 7 which appeared as a main double peak 65 
(63 %) on HPLC analysis (Fig. 2). 
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Scheme 2 Schematic representation of the solid-phase approach used for 
the synthesis of dichloroplatinum(II) conjugates of octreotide. 
 To investigate the stability of such conjugates, 6 (pure cis 70 
isomer) was dissolved in H2O and left to stand at rt. HPLC 
analysis revealed that more than 60% of the product remained 
unaltered after 24 h (Fig. 2) which demonstrates that 
replacement of the disulfide linkage by dicarba isosteres has a 
positive effect on the overall stability of the conjugate. 75 
Interestingly, 6 was completely stable in a 150 mM NaCl 
aqueous solution for 24 h. 
     
 
Fig. 2 Reversed HPLC traces for crude conjugate 6 (a) and 7 (b), and of 
pure 6 cis dissolved in H2O (c) or in 150 mM aqueous NaCl after 24 h (d). 80 
 Since cisplatin and related anticancer drugs effect their 
cytotoxic action at the level of DNA, in particular by 
covalently linking to two adjacent guanines on the same 
strand,1 we examined whether the platinum-octreotide 
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conjugates retain this binding capacity. As a DNA model we 
chose a short synthetic oligonucleotide, 5’dCATGGCT, which 
contains the target GpG doublet and gives the expected intra-
chain Pt-N7/5’G,N7/3’G chelate upon reaction both with 
cisplatin and with [Pt(en)Cl2].
16 The reaction between 6 (cis 5 
isomer purified as a mixture of two diastereomers) and the 
oligonucleotide (1:1) was carried out in H2O at 37ºC (Scheme 
3). As shown by HPLC, three new broad peaks with higher 
retention time than the parent oligonucleotide were slowly 
generated (20% after 24 h). MALDI-TOF MS revealed that an 10 
adduct had been formed between 5’dCATGGCT and 6, and 
that both chloride ligands had been lost in all of them. Indeed, 
MS analysis after enzymatic digestion with 5’- and 3’-
exonucleases (calf spleen and snake venom 
phosphodiesterases, respectively)17 confirmed the formation 15 
of a chelate between the platinum moiety of 6 and the two 
consecutive guanines of the oligonucleotide chain, 8 (Scheme 
3). The presence of more than two Pt-N7/5’G,N7/3’G chelates 
can be attributed to the formation of two positional isomers, 
differing in the orientation of the peptide moiety towards the 20 
oligonucleotide chain. Similarly, reaction with [PtCl2(dap)] (2 
eq) showed three new peaks upon HPLC analysis (relative 
ratio 1:1:1.3) that were isolated and characterized by 
enzymatic digestion as GpG intra-chain chelates 9. Although 
the platination yield of the oligonucleotide was higher with 25 
[PtCl2(dap)] than with 6 (70% vs 20% after 24 h, 
respectively), the platinum(II)-octreotide conjugate, as 
previously showed (Fig. 2), is not completely stable in water. 
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Scheme 3 Formation of the chelate between 6 and the oligonucleotide and 30 
its enzymatic degradation with 5’ and 3’-exonucleases.  
 In conclusion, herein we have described a straightforward 
solid-phase methodology for the synthesis of 
dichloroplatinum(II) complexes conjugated with dicarba 
analogues of octreotide. The fact that these conjugates retain 35 
the ability to bind to DNA in the same way as cisplatin, opens 
the door to their use as anticancer drugs. Conjugation to 
octreotide is expected to increase the concentration of the 
metal-based drug in the tumor tissue through specific 
interations with the somatostatin receptor. It is also expected 40 
to reduce toxicity and side effects. Efforts are under way to 
study the affinity and selectivity of these conjugates for sst 
receptors, as well as to evaluate their biological activity 
toward several cancer cell lines.  
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